FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133589701> ?p ?o ?g. }

• W2133589701 endingPage "433" @default.
• W2133589701 startingPage "427" @default.
• W2133589701 abstract "Background L-Asparaginase is an effective drug in the treatment of childhood acute lymphoblastic leukemia (ALL). The use of L-asparaginase may be limited by serious adverse events of which allergy is the most frequent. The objective of this study was to describe the clinical aspects of PEG-asparaginase allergy in children treated according to the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol. Procedure Children (1–17 years) enrolled in the NOPHO ALL2008 protocol between July 2008 and August 2011, who developed PEG-asparaginase allergy were identified through the NOPHO ALL2008 toxicity registry. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG-asparaginase (Oncaspar®) 1,000 IU/m2/dose administered at 2 or 6 weeks intervals during a total period of 30 weeks. (Clinical trials.gov no: NCT00819351). Results Of 615 evaluable patients, 79 patients developed clinical PEG-asparaginase allergy (cumulative risk; 13.2%) and discontinued PEG-asparaginase therapy for that reason. PEG-asparaginase allergy occurred after a median of two doses (75% range 2–4, max 14). In 58% of PEG-asparaginase hypersensitive patients, the clinical allergic reactions appeared within 2 hr after PEG-asparaginase administration and ranged from mild symptoms to systemic anaphylaxis. Nine patients experienced an anaphylactic reaction within 1 hr and 50 min from asparaginase administration; none were fatal. Four of 68 patients (6%) who subsequently received Erwinase therapy also reacted allergic to Erwinase. Conclusion Clinical allergy to PEG-asparaginase occurred early in treatment, was in general moderate in severity, and mostly developed within 2 hr after PEG-asparaginase administration. The risk of subsequent Erwinase allergic reactions was low. Pediatr Blood Cancer 2015;62:427–433. © 2014 Wiley Periodicals, Inc." @default.
• W2133589701 created "2016-06-24" @default.
• W2133589701 creator A5005257038 @default.
• W2133589701 creator A5012706428 @default.
• W2133589701 creator A5032784001 @default.
• W2133589701 creator A5054376745 @default.
• W2133589701 creator A5061309869 @default.
• W2133589701 creator A5066050875 @default.
• W2133589701 creator A5071720008 @default.
• W2133589701 creator A5074845542 @default.
• W2133589701 creator A5075840216 @default.
• W2133589701 creator A5083075511 @default.
• W2133589701 creator A5085002313 @default.
• W2133589701 date "2014-11-21" @default.
• W2133589701 modified "2023-10-14" @default.
• W2133589701 title "PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol" @default.
• W2133589701 cites W1887863677 @default.
• W2133589701 cites W1965542498 @default.
• W2133589701 cites W1970593462 @default.
• W2133589701 cites W1972467214 @default.
• W2133589701 cites W1978296843 @default.
• W2133589701 cites W1995473821 @default.
• W2133589701 cites W1995905554 @default.
• W2133589701 cites W2000573359 @default.
• W2133589701 cites W2008015982 @default.
• W2133589701 cites W2017265604 @default.
• W2133589701 cites W2018374431 @default.
• W2133589701 cites W2021422854 @default.
• W2133589701 cites W2053852136 @default.
• W2133589701 cites W2058713665 @default.
• W2133589701 cites W2060440673 @default.
• W2133589701 cites W2061069132 @default.
• W2133589701 cites W2074801523 @default.
• W2133589701 cites W2076057372 @default.
• W2133589701 cites W2080051364 @default.
• W2133589701 cites W2096489857 @default.
• W2133589701 cites W2100928838 @default.
• W2133589701 cites W2113512182 @default.
• W2133589701 cites W2117623554 @default.
• W2133589701 cites W2120793327 @default.
• W2133589701 cites W2123774190 @default.
• W2133589701 cites W2127153931 @default.
• W2133589701 cites W2146971143 @default.
• W2133589701 doi "https://doi.org/10.1002/pbc.25319" @default.
• W2133589701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25418987" @default.
• W2133589701 hasPublicationYear "2014" @default.
• W2133589701 type Work @default.
• W2133589701 sameAs 2133589701 @default.
• W2133589701 citedByCount "65" @default.
• W2133589701 countsByYear W21335897012015 @default.
• W2133589701 countsByYear W21335897012016 @default.
• W2133589701 countsByYear W21335897012017 @default.
• W2133589701 countsByYear W21335897012018 @default.
• W2133589701 countsByYear W21335897012019 @default.
• W2133589701 countsByYear W21335897012020 @default.
• W2133589701 countsByYear W21335897012021 @default.
• W2133589701 countsByYear W21335897012022 @default.
• W2133589701 countsByYear W21335897012023 @default.
• W2133589701 crossrefType "journal-article" @default.
• W2133589701 hasAuthorship W2133589701A5005257038 @default.
• W2133589701 hasAuthorship W2133589701A5012706428 @default.
• W2133589701 hasAuthorship W2133589701A5032784001 @default.
• W2133589701 hasAuthorship W2133589701A5054376745 @default.
• W2133589701 hasAuthorship W2133589701A5061309869 @default.
• W2133589701 hasAuthorship W2133589701A5066050875 @default.
• W2133589701 hasAuthorship W2133589701A5071720008 @default.
• W2133589701 hasAuthorship W2133589701A5074845542 @default.
• W2133589701 hasAuthorship W2133589701A5075840216 @default.
• W2133589701 hasAuthorship W2133589701A5083075511 @default.
• W2133589701 hasAuthorship W2133589701A5085002313 @default.
• W2133589701 hasConcept C10138342 @default.
• W2133589701 hasConcept C126322002 @default.
• W2133589701 hasConcept C162324750 @default.
• W2133589701 hasConcept C203014093 @default.
• W2133589701 hasConcept C207480886 @default.
• W2133589701 hasConcept C2775933838 @default.
• W2133589701 hasConcept C2776694085 @default.
• W2133589701 hasConcept C2778461978 @default.
• W2133589701 hasConcept C2778904437 @default.
• W2133589701 hasConcept C2781107101 @default.
• W2133589701 hasConcept C2909962599 @default.
• W2133589701 hasConcept C535046627 @default.
• W2133589701 hasConcept C54400483 @default.
• W2133589701 hasConcept C71924100 @default.
• W2133589701 hasConceptScore W2133589701C10138342 @default.
• W2133589701 hasConceptScore W2133589701C126322002 @default.
• W2133589701 hasConceptScore W2133589701C162324750 @default.
• W2133589701 hasConceptScore W2133589701C203014093 @default.
• W2133589701 hasConceptScore W2133589701C207480886 @default.
• W2133589701 hasConceptScore W2133589701C2775933838 @default.
• W2133589701 hasConceptScore W2133589701C2776694085 @default.
• W2133589701 hasConceptScore W2133589701C2778461978 @default.
• W2133589701 hasConceptScore W2133589701C2778904437 @default.
• W2133589701 hasConceptScore W2133589701C2781107101 @default.
• W2133589701 hasConceptScore W2133589701C2909962599 @default.
• W2133589701 hasConceptScore W2133589701C535046627 @default.
• W2133589701 hasConceptScore W2133589701C54400483 @default.
• W2133589701 hasConceptScore W2133589701C71924100 @default.

• next